1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Hyloris Sets Out Plans To Expand Its Pipeline

Value Added Medicines Company Aims For 14 Commercial Products By 2024

 
• By Akriti Seth

After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024. 

expansion
Hyloris reveals plans to add at least three products to its pipeline in 2021 and commercialize 14 products by 2024 • Source: Shutterstock

ForHyloris Pharmaceuticals SA, 2021 began with pipeline expansion as the company entered into a partnership with Purna Female Healthcare. And the Belgian value-added medicines specialist has revealed that it further plans to expand its pipeline with at least three new products in the coming months.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.